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Summary: Protumorigenic PD-1 hi B cells, induced in hepatocellular carcinoma, suppress tumor-specifi c T-cell response via IL10-dependent pathways upon PD-1/PD-L1 interaction. Anti-PD-1 or anti-PD-L1 antibodies may function not only through blocking the PD-1 coinhibitory pathway in T cells but also via abolishing the suppressive function of regulatory B cells. Cancer Discov; 6(5) ; 477-8. ©2016 AACR. See related article by Xiao et al., p. 546 (7) .
Tumor cells often induce an immunosuppressive microenvironment against antitumor immune responses. Besides regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, regulatory B cells (Breg) have recently been reported to be key immune suppressors that silence antitumor responses and promote tumor progression in some types of tumors. Bregs were fi rst discovered as inhibitors in autoimmune diseases, because B-cell-defi cient mice ( μ MT) failed to control experimental autoimmune encephalomyelitis (EAE) and could not undergo spontaneous remission ( 1 ) . The exacerbated EAE in μ MT mice was later attributed to a defi ciency in IL10-producing B cells ( 2 ), or so-called B10 cells.
Emerging data indicate that tumor-infi ltrating B cells are not irrelevant bystanders in tumor progression, but rather actively regulate antitumor immune responses (3) (4) (5) (6) . Tumor-infi ltrating B cells with distinct phenotypes and functions may play specifi c roles in antitumor responses ( 5 hi Bregs, which suppress tumor-specifi c immunity and promote tumor progression.
Immunosurveillance, as a primary defense against cancer, is a process for the immune system to recognize and destroy tumor cells. However, some tumor cells can escape elimination by the immune system via activation of immunosuppressive feedback loops, which result in the induction of T-cell tolerance and the failure of tumor rejection. PD-1 signaling is one such inhibitory pathway, and its activation has been investigated in several cancer types ( 8 ) . Binding of PD-1 on T cells with PD-L1 on antigen-presenting cells (APC) and other cells is a major mechanism triggering T-cell exhaustion during tumor progression. Costimulatory receptors primarily function to modify T-cell receptor signaling, but PD-1 exhibits a more dominant function in inhibiting IFN γ , TNF α , and IL2 production than in promoting cellular proliferation ( 9 ) . PD-1 can be expressed on T cells, B cells, natural killer T cells, activated monocytes, and dendritic cells ( 9 ) . The role of PD-1 on T cells has been well studied, but this role has not been so well studied in regard to B cells. Xiao ( Fig.  1B ) . These two different pathways can exist separately or coexist in the tumor microenvironment. This mechanism may explain why anti-PD-1 or anti-PD-L1 can also control some tumors with PD-1-negative tumor-infi ltrating T lymphocytes ( 8 ) .
To overcome tumor immune tolerance, identifi cation of the dominant immunosuppressive cells and pathways in the tumor will be an alternative way to redesign future treatment. Each individual tumor microenvironment is possibly controlled by a distinct profi le of suppressive molecules or cellular populations. This study has demonstrated that the PD-1 hi B cell is one sort of immunosuppressive cell that is specifi cally induced in the hepatocellular carcinoma microenvironment. If PD-1 hi B cells are the dominant immunosuppressive cells in HCC, or even in other types of cancer, an anti-CD20 antibody can potentially be used to transiently deplete these cells and remove the suppression ( 10 ) . The authors propose that soluble factors derived from cancer cells promote PD-1 expression. Determining the nature of such factors will bring great benefi t to clinical treatment. In addition to the proposed monocytes, other sources of PD-L1 interaction with PD-1 on B cells cannot yet be ruled out. It would be interesting to know whether B-cell and/or T-cell dysfunction can be corrected by PD-1 blockade on B cells, and whether IL10 production from those Bregs can be suppressed after anti-PD-1 or anti-PD-L1 treatment in the clinic. The requirement of PD-1 or PD-L1 signaling for the generation of those Bregs should be investigated in a follow-up study. Overall, this study has opened a new avenue for the study of B cell-mediated suppression and provided new insights into possible manipulation by B cellmediated suppression through PD-1 overexpression.
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